Form 4 for PFE Pfizer
Accepted 2023-02-24 00:00:00 ET · period of report 2023-02-22 · accession 0001225208-23-002809 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-24 | 2023-02-22 | PFE | DAMICO JENNIFER B. | SVP, Ctrl | F - Tax | $43.44 | -7,944 | 13.6K | -37% | -$345.1K |
| D | 2023-02-24 | 2023-02-22 | PFE | DAMICO JENNIFER B. | SVP, Ctrl | M - OptEx | $30.17 | +10.5K | 21.6K | +94% | +$315.5K |
| D | 2023-02-24 | 2023-02-23 | PFE | DAMICO JENNIFER B. | SVP, Ctrl | A - Grant | $0.00 | +3,103 | 16.7K | +23% | $0 |
| D | 2023-02-24 | 2023-02-22 | PFE | DAMICO JENNIFER B. | SVP, Ctrl | M - OptEx | $0.00 | -10.5K | 0 | -100% | $0 |
| DM | 2023-02-24 | 2023-02-23 | PFE | DAMICO JENNIFER B. | SVP, Ctrl | A - Grant | $0.00 | +22.8K | 10.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-22 | F | D | 1,579 | $42.38 | 20,005 | D | — | — | (F2) The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| 2 | Common | Common Stock | 2023-02-22 | M | A | 10,456 | $30.17 | 21,584 | D | — | — | (F1) The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| 3 | Common | Common Stock | 2023-02-23 | A | A | 3,103 | $0.00 | 16,743 | D | — | — | (F5) The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. |
| 4 | Common | Common Stock | 2023-02-22 | F | D | 6,365 | $43.70 | 13,640 | D | — | — | (F3) The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). (F4) Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| 5 | Derivative | Stock Appreciation Rights | 2023-02-22 | M | D | 10,456 | $0.00 | 0 | D | $30.17 · 2023-02-22 to 2023-02-22 | 10,456 Common Stock | |
| 6 | Derivative | Stock Appreciation Rights | 2023-02-23 | A | A | 12,169 | $0.00 | 12,169 | D | $42.30 · 2028-02-23 to 2028-02-23 | 12,169 Common Stock | (F6) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
| 7 | Derivative | Stock Appreciation Rights | 2023-02-23 | A | A | 10,591 | $0.00 | 10,591 | D | $42.30 · 2030-02-23 to 2030-02-23 | 10,591 Common Stock | (F7) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |